What is the most likely diagnosis and recommended management for a 24‑year‑old male presenting with two weeks of vertigo and imbalance, increased migraine frequency, and mildly elevated total bilirubin and transaminases?

Vestibular Migraine with Incidental Mild Transaminitis

The most likely diagnosis is vestibular migraine, and management should focus on migraine-specific therapy with lifestyle modifications while monitoring the mildly elevated liver enzymes, which likely represent an incidental finding unrelated to the primary neurological presentation.

Primary Diagnosis: Vestibular Migraine

This 24-year-old male's presentation of two weeks of vertigo and imbalance with increased migraine frequency strongly suggests vestibular migraine, which is now recognized as the most common cause of spontaneous episodic vertigo, affecting 1-3% of the general population 1, 2, 3.

Diagnostic Reasoning

• Vestibular migraine typically presents with episodic vertigo lasting minutes to hours (though can extend to days) accompanied by migraine features 4.
• The condition often begins several years after typical migraine onset, and the delay between headache and vertigo may be substantial 3.
• Attacks can occur without concurrent headache, which frequently leads to misdiagnosis 3, 5.
• The two-week duration suggests either prolonged episodes or recurrent attacks, both consistent with vestibular migraine 4, 1.

Key Differential Considerations

Central causes must be excluded, particularly in a young male with new-onset vertigo 4:

• Brainstem or cerebellar stroke: Would typically present with additional posterior circulation signs (dysarthria, dysmetria, dysphagia, sensory/motor deficits, Horner's syndrome) 4.
• Benign paroxysmal positional vertigo (BPPV): Would be triggered specifically by positional changes and respond to repositioning maneuvers 4.
• Ménière's disease: Would include auditory symptoms (hearing loss, tinnitus, aural fullness) as core features 4.

Management Strategy

Acute Treatment

For active vertigo episodes during attacks 4:

• Vestibular suppressants should be offered for a limited course only during acute attacks, not as continuous therapy 4.
• Options include benzodiazepines (with caution regarding dependence risk) or anticholinergics (scopolamine) for symptom control during episodes 4.
• Vestibular suppressants should NOT be used routinely or as primary treatment 4.

For migraine headache component 4, 6:

• NSAIDs (ibuprofen, naproxen sodium, or aspirin) should be offered as first-line acute treatment 4.
• Triptans (sumatriptan, rizatriptan, zolmitriptan) should be used as second-line when NSAIDs are inadequate 4.
• Antiemetics (metoclopramide, domperidone) may be added for nausea 4.
• Limit acute medication use to no more than twice weekly to prevent medication-overuse headache 4.

Preventive Therapy

Given the two-week duration and increased migraine frequency, preventive therapy should be strongly considered 4, 1:

• Preventive treatment is indicated when migraine continues to impair quality of life despite optimized acute therapy, typically when adversely affected ≥2 days per month 4.
• First-line preventive options include beta-blockers, antiepileptics (topiramate, valproate), or tricyclic antidepressants 4, 1, 5.
• Efficacy should be assessed after 2-3 months for oral preventives 4.
• Treatment adherence improves with once-daily dosing 4.

Lifestyle Modifications

Trigger identification and avoidance are essential 4:

• Maintain a headache/vertigo diary documenting severity, frequency, duration, disability, and potential triggers 4.
• Common triggers include stress, fatigue, alcohol, caffeine, specific foods (tyramine, nitrates), perfumes, fumes, glare, and flickering lights 4.
• Limit sodium intake (ideally <1500 mg daily, maximum 2300 mg) as increased sodium can worsen vestibular symptoms 4.
• Ensure adequate sleep, regular exercise, and stress management 4.

Addressing the Laboratory Abnormalities

Transaminitis Assessment

The mildly elevated transaminases (AST 41 IU/L, ALT 104 IU/L) and bilirubin (1.4 mg/dL) require evaluation but are unlikely to be related to the acute vestibular/migraine presentation:

According to British Thoracic Society guidelines for monitoring hepatotoxicity 4:

• With ALT 104 IU/L (2.4× upper limit of normal), liver function should be monitored weekly for two weeks, then biweekly until normal 4.
• If transaminase levels fall on repeat testing, further monitoring is only required if symptoms develop 4.
• If AST/ALT rises to 5× normal or bilirubin rises significantly, hepatotoxic medications should be stopped 4.

Workup for Elevated Liver Enzymes

Before initiating migraine preventive therapy, complete the following evaluation 4:

• Review all medications and supplements for potential hepatotoxicity 4.
• Viral hepatitis serologies (hepatitis A, B, C) 4.
• Iron studies, alcohol history 4.
• Consider autoimmune markers (ANA, ASMA) if suspicion for autoimmune hepatitis 4.
• Abdominal ultrasound if concern for structural liver disease 4.

Medication Selection Considerations

Given the mild transaminitis, medication selection requires careful consideration:

• NSAIDs for acute treatment can be used cautiously with liver enzyme monitoring 4.
• Triptans have minimal hepatic concerns and remain appropriate 4.
• For preventive therapy, avoid valproate initially given hepatotoxic potential; consider beta-blockers (propranolol, metoprolol) or topiramate with close monitoring 4, 1.
• If liver enzymes normalize, standard preventive options become available 4.

Follow-Up Plan

• Repeat liver function tests in one week, then biweekly until normalization 4.
• Reassess vestibular and migraine symptoms in 2-4 weeks after initiating treatment 4.
• If preventive therapy is started, assess efficacy after 2-3 months 4.
• Consider neurology or otolaryngology referral if diagnosis remains uncertain or symptoms persist despite appropriate treatment 4, 1.

Critical Pitfalls to Avoid

• Do not dismiss central causes without proper neurological examination—look specifically for posterior circulation signs 4.
• Do not use vestibular suppressants as primary or continuous therapy—they are only for acute symptom control during attacks 4.
• Do not overlook medication-overuse headache risk—limit acute treatments to twice weekly maximum 4.
• Do not ignore the elevated transaminases—complete appropriate workup and monitor as indicated, but recognize this is likely incidental to the primary vestibular/migraine presentation 4.
• Do not start hepatotoxic preventive medications (valproate) without first normalizing liver enzymes and completing hepatic workup 4.